TNF inhibitors don't cut ACS risk in arthritis patients

01/3/2012 | MedPage Today (free registration)

Researchers found that tumor necrosis factor inhibitors failed to lower acute coronary syndrome risk among patients with early rheumatoid arthritis enrolled in Sweden's national registry from 1999 to 2007. The anti-TNF drugs did not reduce ACS risk even among patients who responded well to the drugs at three months. The study appears in Arthritis & Rheumatism.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX